In this video from Thursday's Market Checkup, Motley Fool health-care analysts David Williamson and Max Macaluso dive into the biggest stories impacting health-care investors on the market today.
In this segment, a look at the biotech losers on the market during the last two days. InterMune (NASDAQ: ITMN ) pulled back 10% yesterday, down a total of 22% during the last five trading sessions, as investors remain concerned about new competition for Esbriet, which is the company's idiopathic pulmonary fibrosis drug. Enanta Pharmaceuticals (NASDAQ: ENTA ) is also down 10%, dragged down by the continuing investor excitement surrounding Gilead and its hepatitis C treatment. Enanta is partners with AbbVie and will get royalties off of AbbVie's own hep. C drug regimen, but investor enthusiasm may be siding with Gilead at the moment. David sees this battle as coming down to relative pricing, and will be watching that closely. And finally, GW Pharmaceuticals (NASDAQ: GWPH ) fell by 7% after reporting solid earnings that beat on the top line yesterday, after its tremendous run up of more than 500% in the past six months, David sees this as potentially a case of investors taking some profit off the table.
So what's the best way to for investors to play the volatile biotech space?
The best way to play the biotech space is to find companies that shun the status quo and, instead, discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report, "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.